FR2922550B1 - Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet - Google Patents

Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet

Info

Publication number
FR2922550B1
FR2922550B1 FR0707314A FR0707314A FR2922550B1 FR 2922550 B1 FR2922550 B1 FR 2922550B1 FR 0707314 A FR0707314 A FR 0707314A FR 0707314 A FR0707314 A FR 0707314A FR 2922550 B1 FR2922550 B1 FR 2922550B1
Authority
FR
France
Prior art keywords
novel
heteroalkyloxy
benzothiazole
medicaments
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0707314A
Other languages
English (en)
Other versions
FR2922550A1 (fr
Inventor
Conception Nemecek
Sylvie Wentzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR0707314A priority Critical patent/FR2922550B1/fr
Priority to PA20088798901A priority patent/PA8798901A1/es
Priority to PCT/FR2008/001450 priority patent/WO2009087305A1/fr
Priority to AU2008346313A priority patent/AU2008346313A1/en
Priority to EP08869645A priority patent/EP2205568A1/fr
Priority to KR1020107010820A priority patent/KR20100075644A/ko
Priority to CA2702791A priority patent/CA2702791A1/fr
Priority to JP2010529425A priority patent/JP2011500651A/ja
Priority to RU2010119934/04A priority patent/RU2010119934A/ru
Priority to MX2010004293A priority patent/MX2010004293A/es
Priority to CN200880112247A priority patent/CN101827827A/zh
Priority to TW097140026A priority patent/TW200922565A/zh
Priority to ARP080104536A priority patent/AR068912A1/es
Priority to CL2008003093A priority patent/CL2008003093A1/es
Priority to PE2008001795A priority patent/PE20090876A1/es
Priority to UY31412A priority patent/UY31412A1/es
Publication of FR2922550A1 publication Critical patent/FR2922550A1/fr
Application granted granted Critical
Publication of FR2922550B1 publication Critical patent/FR2922550B1/fr
Priority to IL205097A priority patent/IL205097A0/en
Priority to US12/761,973 priority patent/US8188078B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
FR0707314A 2007-10-19 2007-10-19 Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet Expired - Fee Related FR2922550B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR0707314A FR2922550B1 (fr) 2007-10-19 2007-10-19 Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
PA20088798901A PA8798901A1 (es) 2007-10-19 2008-10-15 Nuevos derivados de 6- aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de cmet"
AU2008346313A AU2008346313A1 (en) 2007-10-19 2008-10-16 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as c-Met inhibitors
EP08869645A EP2205568A1 (fr) 2007-10-19 2008-10-16 Derives de 6-aryl/heter0alkyl0xy benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
KR1020107010820A KR20100075644A (ko) 2007-10-19 2008-10-16 6-아릴/헤테로알킬옥시 벤조티아졸 및 벤즈이미다졸 유도체, 이들의 제조 방법, 약물로서의 이들의 적용, 제약 조성물, 및 특히 ｃ-ＭＥＴ 억제제로서의 신규 용도
CA2702791A CA2702791A1 (fr) 2007-10-19 2008-10-16 Derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
JP2010529425A JP2011500651A (ja) 2007-10-19 2008-10-16 ６−アリール／ヘテロアルキルオキシベンゾチアゾールおよびベンゾイミダゾール誘導体、これらの調製方法、薬物としてのこれらの用途、医薬組成物、ならびに特にｃ−ｍｅｔ阻害剤としての新規使用
RU2010119934/04A RU2010119934A (ru) 2007-10-19 2008-10-16 Производные 6-арил/гетероалкилокси бензотиазола и бензимидазола, способ их получения, их применение в качестве лекарственных средств, фармацевтические композиции и новое применение, в частности, в качестве ингибиторов смет
MX2010004293A MX2010004293A (es) 2007-10-19 2008-10-16 Derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de cmet.
CN200880112247A CN101827827A (zh) 2007-10-19 2008-10-16 6-芳基/杂烷氧基苯并噻唑和苯并咪唑的衍生物、其制备方法、其作为药物的应用、药物组合物和尤其作为cmet抑制剂的新用途
PCT/FR2008/001450 WO2009087305A1 (fr) 2007-10-19 2008-10-16 Derives de 6-aryl/heter0alkyl0xy benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
ARP080104536A AR068912A1 (es) 2007-10-19 2008-10-17 Derivados de 6- aril/ heteroarilquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y utilizacion como inhibidores de cmet
TW097140026A TW200922565A (en) 2007-10-19 2008-10-17 Novel derivatives of 6-aryl/heteroalkyloxy benzothiazole and benzimidazole, their method of preparation, their application as medicinal products, pharmaceutical compositions and novel use notably as c-MET inhibitors
CL2008003093A CL2008003093A1 (es) 2007-10-19 2008-10-17 Compuestos derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol; procedimiento de preparacion; composicion farmaceutica, y uso para el tratamiento o la prevencion de trastornos de los vasos sanguineos, alergias, asma, trombosis, artritis reumatoide y cancer, entre otras.
PE2008001795A PE20090876A1 (es) 2007-10-19 2008-10-17 Nuevos derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de cmet
UY31412A UY31412A1 (es) 2007-10-19 2008-10-20 Nuevos derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmacéuticas y nueva utilizacion principalmente como inhibidores de cmet
IL205097A IL205097A0 (en) 2007-10-19 2010-04-14 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as c-met inhibitors
US12/761,973 US8188078B2 (en) 2007-10-19 2010-04-16 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0707314A FR2922550B1 (fr) 2007-10-19 2007-10-19 Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet

Publications (2)

Publication Number Publication Date
FR2922550A1 FR2922550A1 (fr) 2009-04-24
FR2922550B1 true FR2922550B1 (fr) 2009-11-27

Family

ID=39304632

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0707314A Expired - Fee Related FR2922550B1 (fr) 2007-10-19 2007-10-19 Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet

Country Status (18)

Country Link
US (1) US8188078B2 (fr)
EP (1) EP2205568A1 (fr)
JP (1) JP2011500651A (fr)
KR (1) KR20100075644A (fr)
CN (1) CN101827827A (fr)
AR (1) AR068912A1 (fr)
AU (1) AU2008346313A1 (fr)
CA (1) CA2702791A1 (fr)
CL (1) CL2008003093A1 (fr)
FR (1) FR2922550B1 (fr)
IL (1) IL205097A0 (fr)
MX (1) MX2010004293A (fr)
PA (1) PA8798901A1 (fr)
PE (1) PE20090876A1 (fr)
RU (1) RU2010119934A (fr)
TW (1) TW200922565A (fr)
UY (1) UY31412A1 (fr)
WO (1) WO2009087305A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (fr) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidines pour le traitement de maladies inflammatoires
KR20100075930A (ko) 2007-10-19 2010-07-05 베링거 인겔하임 인터내셔날 게엠베하 헤테로사이클-치환된 피페라지노-디하이드로티에노피리미딘
UA99309C2 (ru) 2007-10-19 2012-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Замещенные пиперидинодигидротиенопиримидины
US8486948B2 (en) 2007-10-19 2013-07-16 Boehringer Ingelheim International Gmbh Piperazinodihydrothienopyrimidine derivatives
FR2953720B1 (fr) * 2009-12-11 2012-05-11 Oreal Utilisation de derives de benzyloxy-ethylamines comme conservateur,
WO2011138751A2 (fr) 2010-05-04 2011-11-10 Pfizer Inc. Dérivés hétérocycliques destinés au traitement de maladies
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
CN103242237A (zh) * 2013-05-10 2013-08-14 常州亚邦齐晖医药化工有限公司 一种驱虫药芬苯达唑的制备新方法
CN104876878B (zh) * 2014-02-27 2018-04-27 中国科学院广州生物医药与健康研究院 5-芳基酚-2烷基取代脲苯并咪唑类化合物及其应用
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
ES2910071T3 (es) 2018-03-08 2022-05-11 Incyte Corp Compuestos de aminopirazina diol como inhibidores de PI3K-Y
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
CN110903246A (zh) * 2019-12-19 2020-03-24 赵洁 一种用于治疗甲状腺癌的化合物及其组合物和医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2499995A1 (fr) 1981-02-13 1982-08-20 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkylthiomethyl 7-amino thiazolylacetamido cephalosporanique, leur preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus.
LT4726B (lt) * 1998-12-29 2000-11-27 Biochemijos Institutas 5-pakeisti arilalkiloksibenzimidazol-2-ilkarbamino rūgščių metilo esteriai, turintys antihelmintinį aktyvumą
AU2001236698A1 (en) * 2000-02-07 2001-08-14 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
EP1298125A1 (fr) 2001-09-26 2003-04-02 Aventis Pharma S.A. Benzimidazoles substitués et leur usage comme traitement du cancer
FR2868421B1 (fr) 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
EP1674466A1 (fr) * 2004-12-27 2006-06-28 4Sc Ag Derives benzazoles 2,5- et 2-6-disubstitues utiles comme des inhibiteurs de la proteine kinase
WO2006108059A1 (fr) * 2005-04-06 2006-10-12 Exelixis, Inc. Modulateurs c-met modulators et procedes d’utilisation
FR2891273B1 (fr) * 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet

Also Published As

Publication number Publication date
PA8798901A1 (es) 2009-07-23
CA2702791A1 (fr) 2009-07-16
WO2009087305A1 (fr) 2009-07-16
MX2010004293A (es) 2010-05-17
TW200922565A (en) 2009-06-01
PE20090876A1 (es) 2009-08-03
CN101827827A (zh) 2010-09-08
UY31412A1 (es) 2009-05-29
AR068912A1 (es) 2009-12-16
IL205097A0 (en) 2010-11-30
AU2008346313A1 (en) 2009-07-16
CL2008003093A1 (es) 2010-06-11
JP2011500651A (ja) 2011-01-06
US8188078B2 (en) 2012-05-29
EP2205568A1 (fr) 2010-07-14
FR2922550A1 (fr) 2009-04-24
US20100273793A1 (en) 2010-10-28
KR20100075644A (ko) 2010-07-02
RU2010119934A (ru) 2011-11-27

Similar Documents

Publication Publication Date Title
FR2922550B1 (fr) Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
DK2254908T3 (da) Kosmetiske eller farmaceutiske sammensætninger omfattende metalloproteinasehæmmere
ZA201000912B (en) Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives,method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors
BRPI0915897A2 (pt) compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0807718A2 (pt) Composições de enzima digestiva estável, forma de dosagem, embalagem, uso e processo de preparação das referidas composições
BRPI0820899A2 (pt) Formulação cosmética, e, uso da composição
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
SMAP201000003A (it) Composizione, metodo e preparazione di acidi biliari sintetici
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
FR2912149B1 (fr) Utilisation de derives de dioxolane dans des systemes de revetement et formulation de systeme de revetement
BRPI0819232A2 (pt) composto heterocíclico e composição farmacêutica do mesmo
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0920355A2 (pt) composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina
SMT201300080B (it) Derivati di carbammati di alchiltiazoli, loro preparazione e loro utilizzo come inibitori dell'enzima faah
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
BRPI0819202A2 (pt) Derivado heterocíclico, e, composição farmacêutica
FR2891273B1 (fr) NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
FR2941952B1 (fr) Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
UY33128A (es) Derivados de piridinona y composiciones farmacéuticas de los mismos
BRPI0914819A2 (pt) derivados de pirroloindol inibidores de hps90, composições que os contêm e utilização dos mesmos
BRPI0915482A2 (pt) derivados de 2-oxo-alquil-1-piperazin-2-ona, seus processos de preparação e usos, e composições farmacêuticas e medicamentos compreendendo os mesmos
BRPI0912656A2 (pt) formulação farmacêutica sólida
FR2941951B1 (fr) Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
BRPI0913709A2 (pt) "formulação farmacêutica"

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140630